Deltex Medical Group’s Ewan Phillips discusses the £200,000 monitor order, the US being a key market, his thoughts on the UK NHS healthcare and how the company is doing in 2017 in this exclusive interview with DirectorsTalk
Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about its new monitor sales in the US and UK. Ewan explains how the orders came about, the focus
Ewan Phillips, Deltex Medical’s Chief Executive LON:DEMG, commented: “We are encouraged that we have been able to secure capital funding for our ODM monitors from major customers in both the
Deltex Medical Group’s Ewan Phillips discusses the increased range of medical conditions for which South Korea will reimburse the cost of using ODM, what this means for the company, other international markets and whether 2017 will be a good year in this exclusive interview with DirectorsTalk
Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the benefits of the South Korean health authorities decision to increase the range of medical conditions for which
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring, has told DirectorsTalk that the health authorities in South Korea have decided to increase the range of
Deltex Medical Group’s Jonathan Shaw discusses their trading update & platform account RNS released today in this exclusive interview DirectorsTalk
Deltex Medical Group Plc (LON:DEMG) CFO Jonathan Shaw talks to DirectorsTalk about a trading update and a platform account RNS. Jonathan tells us a little more about the two hospitals
Nigel Keen, Deltex Medical LON:DEMG Chairman, said: “Deltex made good progress in 2016. Growing sales traction in the USA, our main focus market, and in other International markets, together with
Deltex Medical Group’s Ewan Phillips discusses their interim results and the three new platform accounts added to their US network in this exclusive interview with DirectorsTalk
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
